HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.

AbstractAIM:
This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH).
PATIENTS AND METHODS:
The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification.
RESULTS:
Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment.
CONCLUSION:
After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.
AuthorsClovis O DA Fonseca, Raphael M Teixeira, Júlio Cesar T Silva, Juliana DE Saldanha DA Gama Fischer, Osório C Meirelles, Jose Alberto Landeiro, Thereza Quirico-Santos
JournalAnticancer research (Anticancer Res) Vol. 33 Issue 12 Pg. 5625-31 (Dec 2013) ISSN: 1791-7530 [Electronic] Greece
PMID24324108 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Monoterpenes
  • perillyl alcohol
Topics
  • Administration, Inhalation
  • Adult
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Brain Neoplasms (drug therapy)
  • Female
  • Glioblastoma (drug therapy)
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Monoterpenes (administration & dosage, therapeutic use)
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: